ETON - Eton Pharma jumps 20% on FDA approval of seizure therapy

• The shares of Eton Pharmaceuticals ( NASDAQ: ETON ), company focused on rare diseases added ~20% in the pre-market Monday after the announcement of FDA approval for Zonisade (zonisamide oral suspension) for the treatment of partial seizures.
• "ZONISADE™ is the first and only FDA-approved oral liquid formulation of zonisamide, and it offers healthcare providers an important new treatment option for their patients with epilepsy," Chief Executive of Eton ( ETON ) Richard Blackburn noted.
• Specifically, the FDA has greenlighted Zonisade oral suspension at 100 mg/5 mL as an adjunctive therapy for partial seizures in those aged 16 years and above with epilepsy.
• In 2021 Feb., Eton ( ETON ) announced a deal under which Azurity Pharmaceuticals agreed to commercialize Zonisade with no marketing expenses from the company.

For further details see: